A study to determine the incidences of secondary tumours diagnosed in CML patients treated with at least one type of TKIs
Latest Information Update: 22 Jul 2020
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 22 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association